✨
AI Summary
- Deck Bio's multi-peptide-MHC-targeted T-cell engagers aim to treat solid tumors.
- Johanna Kaufmann explains the platform and the company's preclinical development journey.
- Focus on novel T-cell engager technology for challenging cancer types.